Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma

Lung Cancer, 05/01/2012

Immunostaining to detect specific mutant EGFR shows a good correlation with mutation analysis and can be used as a screening method to identify patients for tyrosine kinase inhibitors therapy. Immunohistochemistry (IHC) methodology is potentially useful when molecular analysis is not available and for use in small biopsies when material is too scant for molecular tests. Importantly mutation specific antibodies are useful in determining EGFR status in tissues obtained from bone biopsy as decalcification processes used in molecular based studies often result in DNA degradation hindering mutation detection.

Print Article Summary Cat 2 CME Report